Biotech

All Articles

A deeper take a look at Strong Biotech's Ferocious 15

.In this full week's episode of "The Best Line," our company are actually diving in to Ferocious Bio...

Lilly deals with period 2 failure of tau-targeting med

.The confetti is still soaring from Eli Lilly's celebration celebrating the approval of Alzheimer's ...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of substantial leadership hirings, shootings an...

Lykos will certainly talk to FDA to rethink its selection adhering to being rejected of MDMA treatment for post-traumatic stress disorder

.Following an unsatisfactory presenting for Lykos Therapeutics' MDMA prospect for trauma at a recent...

AN 2 one-halfs roll call, stops phase 3 trial after information disappoint

.AN2 Therapeutics is reviewing its organization in feedback to uninspired midphase information, swea...

Merck pays out $700M for bispecific, spying autoimmune position as well as opportunity to test Amgen in cancer

.Merck &amp Co. is spending $700 million beforehand to challenge Amgen in a blood cancer market. The...

Gilead spends J&ampJ $320M to leave licensing package for seladelpar

.With Gilead Sciences about to an FDA decision for its own liver ailment drug seladelpar, the firm h...

' All hands on deck' at Lilly as peers target being overweight market

.CEO David Ricks can easily observe the firms putting together outdoors tents at basecamp responsibl...

Entero giving up workers, moving out of office and also stopping briefly R&ampD

.Bed Liquidators has actually switched Entero Therapeutics white as a piece. The financial instituti...

Exelixis falls ADC after choosing it's no suit for Tivdak

.Exelixis is giving up on its own tissue factor (TF)- targeting antibody-drug conjugate after conclu...